The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC
Jhanelle E. Gray, Michael Schenker, Mehmet Alı Nahıt Şendur et al. · Journal of Thoracic Oncology · 2024
Introduction Poly (adenosine diphosphate–ribose) inhibitors, including olaparib, upregulate programmed cell death ligand 1, which may increase the efficacy of anti–programmed cell death protein 1 and anti–programmed cell death ligand 1 therapies. Methods In the phase 3 KEYLYNK-006 trial (NCT03976323), eligible adults with previously untreated metastatic nonsquamous NSCLC without targetable genetic alterations who had complete response, partial response, or stable disease after induction therapy with four cycles of pembrolizumab 200 mg every three weeks, pemetrexed 500 mg/m 2 , and carboplatin area under the concentration-time curve 5 mg/mL/min or cisplatin 75 mg/m 2 were randomized in a one-to-one ratio to olaparib 300 mg orally twice daily or pemetrexed every three weeks, both given with up to 31 cycles of pembrolizumab every three weeks. Dual primary endpoints were progression-free survival (PFS) and overall survival (OS). Progression-free survival was tested at interim analysis 2 (i.e., final PFS analysis) and OS at final analysis (FA). Results Of 1003 patients who received induction therapy, 672 (67.0%) were randomized to pembrolizumab plus olaparib (n = 337) or pembrolizumab plus pemetrexed (n = 335) in the intention-to-treat population. Median follow-up at FA was 39.9 (range: 28.1–51.5) months. At interim analysis 2, the median (95% confidence interval [CI]) PFS was 7.1 (5.6–8.7) months versus 8.3 (6.9–11.5) months in the olaparib versus pemetrexed groups (hazard ratio = 1.12, 95% CI: 0.92–1.36, p = 0.87). At FA, the median (95% CI) OS was 20.7 (18.0–24.8) months versus 23.0 (19.0–26.4) months (hazard ratio = 1.04, 95% CI: 0.87–1.25, p = 0.6649). Grade 3 to 5 maintenance treatment-related adverse events occurred in 26.1% versus 30.1% of patients, respectively. Conclusion Pembrolizumab plus maintenance olaparib did not improve PFS or OS versus pembrolizumab plus pemetrexed in previously untreated metastatic nonsquamous NSCLC without targetable genetic alterations.
Cited by 12 works. doi:10.1016/j.jtho.2024.10.026 Open-access PDF
Authors
- Jhanelle E. Gray
- Michael Schenker
- Mehmet Alı Nahıt Şendur
- V.O. Leonova
- Dariusz Mirosław Kowalski
- Terufumi Kato
- Рашида Вахидовна Орлова
- James Chih-Hsin Yang
- Adrian Langleben
- Arnold Pilz
- Andrei Ungureanu
- Milena Perez Mak
- Flávia De Angelis
- Himani Aggarwal
- Bin Zhao
- Mark Shamoun
- Tae Min Kim
References
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
- PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
- PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
- Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy